Unmet Needs in R/R Follicular Lymphoma (FL)
FL is a chronic and incurable disease that typically responds to first-line treatment but inevitably relapses.
Disease Education
Empowering the Immune System to Fight Cancer With CAR-T
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
Explore Clinical Trials
Explore Clinical Trials
All, DLBCL
PICTOR
Prospective Registry to Assess Long-Term Safety or Tisagenlecleucel in Patients With B-Cell Malignancies
1L ALL
CASSIOPEIA
Study of Tisagenlecleucel in 1L HR Pediatric and Young-Adult Patients with B-ALL Who Are MRD Positive at the EOC Therapy
ALL, CLL, DLBCL, SLL
NCT03960840
CD19-Specific CAR-T Cells (YTB323) in Adult Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Diffuse Large B-Cell Lymphoma
R/R MM
PHE885
BCMA-directed CAR-T Cells in adults with R/R MM
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Explore Compounds
Explore Compounds
Tisagenlecleucel (CTL019)
CD19-targeted CAR-T cell therapy
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
CAR-T = chimeric antigen receptor T-cell.
